Difference between revisions of "Part:BBa K4165143"

Revision as of 18:10, 5 October 2022

KNT Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK), its amino acid sequence is KNTPQHRKLRLS. It can penetrate cell membrane and cytosol of N2a cells Sequence and Features

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
COMPATIBLE WITH RFC[25]
1000
COMPATIBLE WITH RFC[1000]

Reference

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.

@@ Line 5: / Line 5: @@
 Tau binding peptide targeting the PHF seed of Tau
-<!-- Add more about the biology of this part here
 ===Usage and Biology===
+KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK), its amino acid sequence is KNTPQHRKLRLS. It can penetrate cell membrane and cytosol of N2a cells
 <!-- -->
 <span class='h3bb'>Sequence and Features</span>
 <partinfo>BBa_K4165143 SequenceAndFeatures</partinfo>
+===Reference===
+. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.
 <!-- Uncomment this to enable Functional Parameter display